Lwl-Klinik Dortmund
- Address
- Marsbruchstrasse 179, Aplerbeck, 44287 Dortmund, Germany
LWL-Klinik Dortmund - Center for Psychiatric Research
LWL-Klinik Dortmund is a specialized psychiatric research center with extensive expertise in severe mental health disorders. The facility focuses on advancing treatment strategies for patients with complex psychiatric conditions, particularly investigating novel pharmacological interventions and optimized treatment protocols for individuals who experience inadequate responses to first-line therapies.
- Schizophrenia and cognitive impairment research, including long-term safety studies of innovative compounds like Iclepertin
- Major depressive disorder and treatment-resistant depression management strategies
- Bipolar disorder research with focus on depressive episodes and treatment optimization
- Early treatment intensification protocols for patients with first-time treatment failures
The center demonstrates particular strength in comparative effectiveness research, conducting randomized controlled trials that evaluate early-intensified pharmacological interventions against treatment-as-usual approaches. Their research methodology emphasizes standardized assessment tools such as the Montgomery Åsberg Depression Rating Scale (MADRS) and Positive And Negative Syndrome Scale (PANSS) to measure treatment response and symptom severity changes. Through participation in multinational studies including the CONNEX clinical trial program, LWL-Klinik Dortmund contributes vital data on both safety profiles and therapeutic efficacy in psychiatric populations with challenging-to-treat conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 1 therapeutic areas and 15 of 50 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 49 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Lwl-Klinik Dortmund
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of AP707 in Patients with Borderline Personality Disorder: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial | Apurano Pharmaceuticals GmbH | Phase II | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 50 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bupropion Hydrochloride | 2 | Unknown | 2024-08-29 | 2025-02-11 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.